R.American egulators say there is “evidence.” Exceptionally persuasive ”of that drug Aducanumabfrom the pharmaceutical company Biogen Inc, works to treat Alzheimer’s disease, one of the most common forms of dementia.
The new treatment could be formally approved in the United States next month. March, as reported in an article published in The Sun.
According to the New England Journal of Medicine, the last drug approved for Alzheimer’s disease was Mematine, which the drug and food regulatory agency FDA (Food and Drugs Administration) valid in 2003.
The latter treatment works by attacking toxic proteins in the brain, also known as amyloids.
When taken in high doses, it can slow mental decline by a quarter over a period of 12 months.
Among those who die from this condition, many have plaques amyloid in their brains.
According to American experts, the treatment is able to artificially create an antibody which then sticks to the plate and destroys it.
However, the Aducanumab it is not a cure for neurological diseases.
So far millions of dollars have been invested in medicine and a statement a FDA said: “the candidate [Biogen Inc] provided substantial medical and scientific evidence of effectiveness of the drug that support its approval “.
Always be the first to know.
Follow the site chosen for the fourth consecutive year Consumer Choice.
Download our free App.